Tuesday, April 28, 2026
← Back to archivePolicy
Policy•KFF•Apr 28, 2026
Health Care’s AI Disruption, Ready or Not
background ▾
- •U.S. health care's unique combination of size (18.3% of GDP), labor intensity, and fragmentation makes it the most vulnerable industrial sector to generative AI disruption, with initial deployment focusing on labor substitution and productivity augmentation.
- •The health care industry lacks adequate preparation and governance frameworks for managing AI's consequences across clinical safety, payment models, and regulatory oversight—a gap KFF is addressing through an extended investigative series.
- •Monitor KFF's ongoing series for substantive findings on AI's clinical safety implications, regulatory policy recommendations, and coverage/payment model impacts as the investigation unfolds.
Policy•KFF•Apr 27, 2026
Abortion in the United States Dashboard
background ▾
- •FDA's mifepristone safety decisions are scientifically grounded, though public perception remains negative, with fewer adults believing abortion pills are safe compared to two years ago
mifepristone
→ Read original articlePolicy•STAT News•Apr 27, 2026
New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project
background ▾
- •Mathematical modeling studies predict 69-628 additional hepatitis B infections annually depending on vaccination coverage rates, with up to $16M in extra healthcare costs per birth cohort under the new CDC-endorsed targeted vaccination policy.
- •The ACIP appears to have bypassed its standard evidence-review process before adopting this controversial recommendation, a departure from historical practice that has prompted legal challenge and state-level resistance.
- •Watch for federal court resolution of the ACIP restructuring lawsuit and whether states formally adopt or reject the new policy; regulatory or legislative intervention may follow if litigation succeeds.
hepatitis B vaccine
→ Read original articlePolicy•Fierce Pharma•Apr 28, 2026
FDA lambasts Incyte over ‘misleading’ Niktimvo claims
background ▾
- •FDA issued a warning letter to Incyte for misleading promotional claims regarding Niktimvo's cGVHD indication
- •Enforcement action signals heightened FDA scrutiny of post-approval promotional practices and labeling claims
- •Monitor for Incyte's corrective actions and any impact on Niktimvo's market positioning in cGVHD
IncyteNiktimvo
→ Read original articlePolicy•Fierce Pharma•Apr 28, 2026
Lessons from the eye: How cell therapy is shaping the future of regenerative medicine
background ▾
- •Astellas is positioning cell therapy as a key pillar of its regenerative medicine strategy going forward
Astellas
→ Read original articleMarket Access
Market Access•Fierce Pharma•Apr 28, 2026
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
background ▾
- •Sun Pharma's $11.75B acquisition of Organon is the largest biopharma M&A transaction in 2026, doubling Sun's revenue base to approximately $12.4B in combined annual sales
- •The deal represents a strategic shift for Sun from generics-focused business toward specialty pharmaceuticals and women's health, a high-margin therapeutic area
- •Watch for details on integration timeline, debt financing plans, R&D consolidation strategy, and impact on both companies' pipeline prioritization and geographic expansion
Sun PharmaOrganon
→ Read original articleMarket Access•Fierce Biotech•Apr 27, 2026
Ligand snaps up fellow biotech royalty aggregator Xoma for $739M
background ▾
- •Ligand nearly doubles its royalty portfolio by acquiring Xoma, adding 120+ assets including 14 in late-stage development, with management projecting ~100% operational synergies and no need for incremental commercial, manufacturing, or clinical infrastructure
- •Deal immediately accretive; Ligand raises 2026 revenue guidance to $270-310M (from $245-285M) with royalty proceeds expected to reach $225-250M, signaling confidence in Xoma's portfolio quality and growth trajectory
- •Xoma's pending litigation with Janssen over Tremfya IP represents material contingent value, with shareholders entitled to 75% of net proceeds from 'certain pending litigation'—outcome and timing of this dispute should be monitored as a material risk/upside factor
Ligand PharmaceuticalsXoma RoyaltyRocheVabysmoOjemdaMiplyffa
→ Read original articleMarket Access•Fierce Biotech•Apr 28, 2026
Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works
background ▾
- •Novartis is strategically building its own CAR-T portfolio rather than chasing expensive in vivo acquisitions, signaling disciplined capital allocation against industry M&A momentum
- •CEO confirmed no active in vivo CAR-T acquisition targets but will evaluate opportunistically, indicating selective openness if valuations or science prove compelling
- •Recent $2B Excellergy and $2B Synnovation deals reflect Novartis's focused approach to pipeline replenishment amid generic competition—a model likely to continue rather than shift toward larger in vivo buys
NovartisEli LillyVyriadrapcabtagene autoleucelEntrestoTasigna
→ Read original articleMarket Access•Fierce Biotech•Apr 27, 2026
Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm
background ▾
- •Thermo Fisher divesting $645M revenue microbiology unit to Astorg PE firm signals portfolio optimization as the company focuses capital on higher-growth areas like its recent $9B Clario acquisition
- •The microbiology business operates in structurally favorable markets driven by infection complexity, stringent food safety standards, and pharma quality control requirements—likely attractive characteristics that supported the $1.075B valuation
- •Monitor Q2 earnings disclosure for detailed EPS dilution impacts and Thermo Fisher's strategic rationale for divestiture versus retention of adjacent diagnostics assets
Thermo Fisher ScientificAstorg
→ Read original articleMarket Access•Fierce Pharma•Apr 28, 2026
Astellas counts on new medicines to offset projected Xtandi decline in fiscal 2026
background ▾
- •Xtandi revenue is expected to decline 5.3% in FY2026 after reaching $6 billion in FY2025, suggesting the drug has entered a mature/declining phase
- •Astellas is explicitly dependent on new product launches to compensate for Xtandi's projected revenue erosion, indicating pipeline execution risk
Astellas PharmaXtandi (enzalutamide)
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 27, 2026
Compass Therapeutics’ stock heads south after cancer bispecific misses on overall survival
background ▾
- •Tovecimig missed the secondary overall survival endpoint (8.9 months vs. 9.4 months for chemotherapy alone), directly contradicting the strong PFS benefit (56% reduction in disease progression risk) and creating a critical efficacy paradox that raises approvability questions
- •High crossover contamination (55% of control arm) rendered the company's RPSFT OS analysis "largely uninterpretable," forcing reliance on post-hoc arguments about pooled survival data and crossover patient outcomes—a weak position for FDA negotiation
- •Critical regulatory inflection point: FDA pre-BLA meeting feedback expected mid-2026 will determine whether accelerated or standard approval pathway is viable; OS miss may force requirement for additional trial data or restrict indication scope
Compass Therapeuticstovecimig
→ Read original articleClinical Trials•Fierce Biotech•Apr 28, 2026
Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered
background ▾
- •Survodutide's 13.4% placebo-adjusted weight loss underperforms established competitors (Zepbound 17.8%, Wegovy 12.4%), but efficacy differentiation remains unproven pending disclosure of cardiometabolic and liver health outcomes
- •Phase 3 tolerability and safety data absent from topline readout despite Phase 2 discontinuation rate of 24.6%, creating significant uncertainty about whether flexible titration and antiemetics resolved gastrointestinal adverse events
- •Watch for upcoming Phase 3 results from trials in patients with comorbidities (liver disease, cardiovascular disease, kidney disease) and MASH studies that may establish clinical differentiation and confirm safety profile
Boehringer IngelheimNovo NordiskEli LillysurvodutideWegovyZepbound
→ Read original articleClinical Trials•Fierce Biotech•Apr 27, 2026
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
background ▾
- •ORKA-001 achieved 63.5% complete skin clearance in phase 2a (40/63 patients), substantially exceeding Skyrizi's labeled 51% and meeting primary endpoint with strong statistical separation from placebo (1/21)
- •Extended half-life enabling potential annual dosing would be unprecedented for IL-23 inhibitors if confirmed; Skyrizi requires maintenance dosing every 12 weeks, potentially simplifying the treatment paradigm
- •Phase 3 design decisions—particularly whether Oruka pursues head-to-head comparison against Skyrizi or other competitors—will be critical for differentiation; clean safety profile supports advancement but must be validated in larger, longer trials
Oruka TherapeuticsAbbVieORKA-001Skyrizi
→ Read original articleClinical Trials•Fierce Biotech•Apr 27, 2026
Astellas thins early pipeline, swaps out struggling rare disease gene therapy
background ▾
- •AT132 development halted after years of safety concerns (4 deaths from liver failure in prior trial) despite Astellas' $3B Audentes acquisition; company pivot to ASP2957 suggests earlier candidate may not advance
- •ASP2957 features superior muscle-targeting AAV capsid with reduced hepatic tropism, enabling substantially lower dosing—a potential competitive advantage if preclinical promise translates clinically
- •Watch for ASP2957 phase 1/2 data readouts from ASPIRO trial and whether improved safety/efficacy profile can rebuild investor confidence in Astellas' gene therapy strategy post-AT132 setback
Astellas PharmaAudentes TherapeuticsKate TherapeuticsAT132resamirigene bilparvovecASP2957
→ Read original articleClinical Trials•Fierce Pharma•Apr 28, 2026
Mundipharma, CorMedix eye antifungal expansion after Rezzayo trial win
background ▾
- •Rezzayo demonstrated efficacy in preventing invasive fungal disease in a clinically significant high-risk transplant population, supporting label expansion beyond current indications
- •Positive data strengthens commercial potential and may accelerate discussions with regulatory authorities and payers for reimbursement in this indication
- •Monitor for regulatory submissions (IND/BLA amendments), additional trial announcements, and partnership/licensing developments as the companies pursue expansion strategy
MundipharmaCorMedixRezzayo
→ Read original article